FLAM
First Light Asset Management Portfolio holdings
AUM
$771M
This Quarter Return
+44.48%
1 Year Return
+33.17%
3 Year Return
+208.13%
5 Year Return
+426.73%
10 Year Return
+3,318.8%
AUM
$1.35B
AUM Growth
+$1.35B
(+38%)
Cap. Flow
+$111M
Cap. Flow
% of AUM
8.23%
Top 10 Holdings %
Top 10 Hldgs %
52.62%
Holding
81
New
21
Increased
33
Reduced
4
Closed
7
Top Buys
| 1 |
Arrowhead Research
ARWR
|
$31.8M |
| 2 |
Health Catalyst
HCAT
|
$31.4M |
| 3 |
Halozyme
HALO
|
$28.4M |
| 4 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$26.6M |
| 5 |
Prothena Corp
PRTA
|
$24.7M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$134M |
| 2 |
AMRN
Amarin Corp
AMRN
|
$9.41M |
| 3 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$9.22M |
| 4 |
KORU Medical Systems
KRMD
|
$8.34M |
| 5 |
CareDx
CDNA
|
$7.43M |
Sector Composition
| 1 | Healthcare | 86.3% |
| 2 | Communication Services | 3.46% |
| 3 | Energy | 0.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CareDx
CDNA
$727M
| $130M | 9.58% | 1,787,637 -102,576 | -5% | -$7.43M |
|
|
2
Halozyme
HALO
$8.56B
| $110M | 8.13% | 2,571,892 +665,103 | +35% | +$28.4M |
|
|
SPNE
3
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $93.4M | 6.91% | 5,351,493 +246,256 | +5% | +$4.3M |
|
|
OXFD
4
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $86.4M | 6.39% | 4,946,629 +307,430 | +7% | +$5.37M |
|
|
5
Arrowhead Research
ARWR
$3.05B
| $54.1M | 4% | 704,449 +413,962 | +143% | +$31.8M |
|
6
Omnicell
OMCL
$1.5B
| $52.8M | 3.91% | 440,246 +19,892 | +5% | +$2.39M |
|
7
Glaukos
GKOS
$5.5B
| $51M | 3.78% | 678,307 +28,018 | +4% | +$2.11M |
|
|
MODN
8
DELISTED
MODEL N, INC.
MODN
| $46.7M | 3.46% | 1,310,013 +378,046 | +41% | +$13.5M |
|
9
AtriCure
ATRC
$1.84B
| $45.1M | 3.33% | 809,310 +248,292 | +44% | +$13.8M |
|
|
10
Health Catalyst
HCAT
$239M
| $42.3M | 3.13% | 971,897 +721,144 | +288% | +$31.4M |
|
11
Axogen
AXGN
$743M
| $38.3M | 2.83% | 2,139,134 +409,699 | +24% | +$7.33M |
|
12
Insmed
INSM
$28.8B
| $35.7M | 2.64% | 1,071,219 +45,878 | +4% | +$1.53M |
|
|
13
KORU Medical Systems
KRMD
$195M
| $35.3M | 2.62% | 5,871,364 -1,385,902 | -19% | -$8.34M |
|
14
Teva Pharmaceuticals
TEVA
$21.1B
| $32.7M | 2.42% | 3,391,412 +1,531,387 | +82% | +$14.8M |
|
15
Y-mAbs Therapeutics
YMAB
$388M
| $31.5M | 2.33% | 635,652 +27,459 | +5% | +$1.36M |
|
16
Ultragenyx Pharmaceutical
RARE
$2.89B
| $29.6M | 2.19% | 213,887 +28,917 | +16% | +$4M |
|
17
Krystal Biotech
KRYS
$4.27B
| $29.5M | 2.18% | 491,740 +27,077 | +6% | +$1.62M |
|
|
XENT
18
DELISTED
Intersect ENT, Inc
XENT
| $28M | 2.07% | 1,222,961 +34,427 | +3% | +$788K |
|
19
NeoGenomics
NEO
$1.13B
| $27.8M | 2.06% | 517,091 -96,011 | -16% | -$5.17M |
|
|
FPRX
20
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $26.6M | 1.97% | +1,563,618 | New | +$26.6M |
|
21
Genmab
GMAB
$15.3B
| $25.9M | 1.92% | 637,084 +33,214 | +6% | +$1.35M |
|
22
Tandem Diabetes Care
TNDM
$845M
| $25.6M | 1.89% | 267,274 +10,069 | +4% | +$963K |
|
|
ARNA
23
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $24.7M | 1.83% | 321,967 +56,628 | +21% | +$4.35M |
|
|
24
Prothena Corp
PRTA
$441M
| $24.7M | 1.83% | +2,056,453 | New | +$24.7M |
|
25
OptimizeRx
OPRX
$335M
| $21.4M | 1.58% | 685,700 +95,700 | +16% | +$2.98M |
|